Evidence map›Paper›PMID 25919612›Full record

ArticleBritish journal of cancer2015

Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening.

V T Nghiem, K R Davies, J R Beck, M Follen, C MacAulay, M Guillaud, S B Cantor

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Overtreatment and Cost-Effectiveness of the See-and-Treat Strategy for Managing Cervical Precancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

V T Nghiem1] The University of Texas MD Anderson Cancer Center, Department of Health Services Research, 1515 Holcombe Blvd., Houston, TX 77030, USA [2] The University of Texas School of Public Health, Division of Management, Policy and Community Health, 1200 Pressler Street, Houston, TX 77030, USA.
K R DaviesThe University of Texas MD Anderson Cancer Center, Department of Health Services Research, 1515 Holcombe Blvd., Houston, TX 77030, USA.
J R BeckFox Chase Cancer Center, Cancer Prevention and Control Program, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
M FollenBrookdale University Hospital & Medical Center, Department of Obstetrics & Gynecology, One Brookdale Plaza, Brooklyn, NY 11212, USA.
C MacAulayBritish Columbia Cancer Research Centre, Integrative Oncology Department, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada.
M GuillaudBritish Columbia Cancer Research Centre, Integrative Oncology Department, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada.
S B CantorThe University of Texas MD Anderson Cancer Center, Department of Health Services Research, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Canadian Centre for Applied Research in Cancer Control · CAThe University of Texas MD Anderson Cancer Center · USBrookdale University Hospital and Medical Center · USFox Chase Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Technical FeasibilityP01CA082710 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GUILLAUD, MARTIAL · 1999 to 2014
$28.7M
BEHAVIORAL SCIENCE EDUCATION--CANCER PREVENTION/CONTROLR25CA057712 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MULLEN, PATRICIA DOLAN · 1992 to 2017
$8.6M
NCI NIH HHS CA016672NCI NIH HHS P01 CA082710NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA016672NCI NIH HHS R25 CA057712NCI NIH HHS R25 CA57712
6 · The paper itself

Abstract

backgroundDNA ploidy analysis involves automated quantification of chromosomal aneuploidy, a potential marker of progression toward cervical carcinoma. We evaluated the cost-effectiveness of this method for cervical screening, comparing five ploidy strategies (using different numbers of aneuploid cells as cut points) with liquid-based Papanicolaou smear and no screening.

methodsA state-transition Markov model simulated the natural history of HPV infection and possible progression into cervical neoplasia in a cohort of 12-year-old females. The analysis evaluated cost in 2012 US$ and effectiveness in quality-adjusted life-years (QALYs) from a health-system perspective throughout a lifetime horizon in the US setting. We calculated incremental cost-effectiveness ratios (ICERs) to determine the best strategy. The robustness of optimal choices was examined in deterministic and probabilistic sensitivity analyses.

resultsIn the base-case analysis, the ploidy 4 cell strategy was cost-effective, yielding an increase of 0.032 QALY and an ICER of $18 264/QALY compared to no screening. For most scenarios in the deterministic sensitivity analysis, the ploidy 4 cell strategy was the only cost-effective strategy. Cost-effectiveness acceptability curves showed that this strategy was more likely to be cost-effective than the Papanicolaou smear.

conclusionCompared to the liquid-based Papanicolaou smear, screening with a DNA ploidy strategy appeared less costly and comparably effective.

Indexed as

PloidiesCohort StudiesCost-Benefit AnalysisCytological TechniquesDNAEarly Detection of CancerFemaleHumansMarkov ChainsVaginal SmearsDNA

Identifiers

PMID25919612
PMCPMC4580387
OpenAlexW1991282910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.